{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:16:48Z","timestamp":1765369008384},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T00:00:00Z","timestamp":1430784000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s11096-015-0128-x","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T03:26:01Z","timestamp":1430709961000},"page":"844-850","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Statin-associated ocular disorders: the FDA and ADRAC data"],"prefix":"10.1007","volume":"37","author":[{"given":"Vinci","family":"Mizranita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eko Harry","family":"Pratisto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,5]]},"reference":[{"issue":"10","key":"128_CR1","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.amjcard.2014.02.034","volume":"113","author":"EP Navarese","year":"2014","unstructured":"Navarese EP, Kowalewski M, Andreotti F, van Wely M, Camaro C, Kolodziejczak M, et al. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2014;113(10):1753\u201364.","journal-title":"Am J Cardiol"},{"key":"128_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","volume":"88","author":"CR Sirtori","year":"2014","unstructured":"Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3\u201311.","journal-title":"Pharmacol Res"},{"key":"128_CR3","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","volume":"370","author":"J Armitage","year":"2007","unstructured":"Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781\u201390.","journal-title":"Lancet"},{"key":"128_CR4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/pds.1895","volume":"19","author":"K Hedenmalm","year":"2010","unstructured":"Hedenmalm K, Alvan G, Ohagen P, Dahl M-L. Muscle toxicity with statins. Pharmacoepidemiol Drug Saf. 2010;19:223\u201331.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"128_CR5","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ophtha.2008.08.006","volume":"115","author":"FW Fraunfelder","year":"2008","unstructured":"Fraunfelder FW, Richards AB. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Ophthalmology. 2008;115:2282\u20135.","journal-title":"Ophthalmology"},{"key":"128_CR6","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archopht.126.8.1111","volume":"126","author":"S Vitale","year":"2008","unstructured":"Vitale S, Ellwein L, Cotch MF, Ferris FL 3rd, Sperduto R. Prevalence of refractive error in the United States, 1999\u20132004. Arch Ophthalmol. 2008;126:1111\u20139.","journal-title":"Arch Ophthalmol"},{"key":"128_CR7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/14740338.2.4.411","volume":"2","author":"FW Fraunfelder","year":"2003","unstructured":"Fraunfelder FW. Ocular adverse drug reactions. Expert Opin Drug Saf. 2003;2:411\u201320.","journal-title":"Expert Opin Drug Saf"},{"key":"128_CR8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/mus.21074","volume":"38","author":"SJ Oh","year":"2008","unstructured":"Oh SJ, Dhall R, Young A, Morgan MB, Lu L, Claussen GC. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008;38:1101\u20137.","journal-title":"Muscle Nerve"},{"key":"128_CR9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000078758","volume":"18","author":"P Irimia","year":"2004","unstructured":"Irimia P, Moya M, Sepulcre J, Martinez-Vila E. Transient blurred vision as the only manifestation of basilar stenosis. Cerebrovasc Dis. 2004;18:88\u20139.","journal-title":"Cerebrovasc Dis"},{"key":"128_CR10","first-page":"427","volume":"118","author":"GJ Negevesky","year":"2000","unstructured":"Negevesky GJ, Kolsky MP, Laureno R, Yau TH. Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia. Arch Ophthalmol. 2000;118:427\u20138.","journal-title":"Arch Ophthalmol"},{"key":"128_CR11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.clinthera.2008.05.017","volume":"30","author":"J Sasaki","year":"2008","unstructured":"Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30:1089\u2013101.","journal-title":"Clin Ther"},{"key":"128_CR12","unstructured":"American Academy of Ophthalmology. [cited 1 August 2014]. http:\/\/www.aao.org\/ ."},{"key":"128_CR13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/157488609789006949","volume":"4","author":"J Beltowski","year":"2009","unstructured":"Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins\u2014mechanisms and consequences. Curr Drug Saf. 2009;4:209\u201328.","journal-title":"Curr Drug Saf"},{"key":"128_CR14","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1210\/jc.2009-2689","volume":"95","author":"RH Eckel","year":"2010","unstructured":"Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab. 2010;95:2015\u201322.","journal-title":"J Clin Endocrinol Metab"},{"key":"128_CR15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/108076804773710858","volume":"20","author":"FW Fraunfelder","year":"2004","unstructured":"Fraunfelder FW. Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors. J Ocul Pharmacol Ther. 2004;20:179\u201382.","journal-title":"J Ocul Pharmacol Ther"},{"key":"128_CR16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1017\/S0317167100007514","volume":"35","author":"SK Baker","year":"2008","unstructured":"Baker SK, Samjoo IA. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci. 2008;35:8\u201321.","journal-title":"Can J Neurol Sci"},{"key":"128_CR17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/138161209787315729","volume":"15","author":"VG Athyros","year":"2009","unstructured":"Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des. 2009;15:479\u201389.","journal-title":"Curr Pharm Des"},{"key":"128_CR18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.iop.0000217573.90522.48","volume":"22","author":"FS Ertas","year":"2006","unstructured":"Ertas FS, Ertas NM, Gulec S, Atmaca Y, Tanju S, Sener C, et al. Unrecognized side effect of statin treatment: unilateral blepharoptosis. Ophthalmic Plast Reconstr Surg. 2006;22:222\u20134.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"128_CR19","unstructured":"MIMS Australia 2014, \u2018Statin\u2019, MIMS Online, Sydney, viewed 25 August 2014. http:\/\/www.mimsonline.com.au.\/Search\/Search.aspx."},{"key":"128_CR20","unstructured":"World Health Organization. Glossary of terms used in Pharmacovigilance. 2015 [cited 1 April 2015]. who-umc.org\/Graphics\/24729.pdf."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0128-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-015-0128-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0128-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T01:54:51Z","timestamp":1559354091000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-015-0128-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["128"],"URL":"https:\/\/doi.org\/10.1007\/s11096-015-0128-x","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,5]]}}}